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Since the start of the clinical vascularized composite allotransplantation (VCA) era over a decade ago this field has witnessed
significant developments in both basic and translational research. Transplant tolerance, defined as rejection-free acceptance of
transplanted organs or tissues without long-term immunosuppression, holds the potential to revolutionize the field of VCA by
removing the need for life-long immunosuppression. While tolerance of organ and vascularized composite transplants may be
induced in small animal models by a variety of protocols, only mixed-chimerism-based protocols have successfully bridged the
gap to preclinical study and to clinical trial in solid organ transplantation to date. In this paper we review the mixed-chimerism
approach to tolerance induction, with specific reference to the field of VCA transplantation, and provide an overview of some
novel cellular therapies as potential adjuvants to mixed chimerism in the development of tolerance induction protocols for clinical
vascularized composite allotransplantation.
1. Introduction
The challenges of transplantation have engaged plastic and
reconstructive surgeons since the early years of the specialty
[1]. During the past decade, since the start of the clinical
vascularized composite allotransplantation era, progress in
this field has accelerated, with significant developments in
both basic and translational research [2, 3].
Currently, vascularized composite allotransplantation
remains dependent on long-term immunosuppression in
order to prevent graft rejection. While modern immuno-
suppressive medications are effective in controlling acute
rejection, they have little impact on chronic rejection;
an incompletely understood phenomenon, observed in all
branches of solid organ transplantation, which leads to a pro-
gressive decline in transplant function [4]. The requirement
for life-long immunosuppression, and the attendant risks
and side effects of current regimens which include metabolic
disorders, renal impairment, infectious complications and an
increased risk of tumor development, present a major cause
for concern in the treatment of conditions which are not,
in contrast to solid organ transplantation, immediately life
threatening.
Induction of donor specific transplant tolerance, defined
as the specific absence of a destructive immune response to
a transplanted tissue in the absence of immunosuppression,
is a primary goal of transplantation research, and holds the
potential to avoid the risks posed by long-term immunosup-
pressive regimens. Tolerance would also overcome chronic
rejection, the impact of which on VCA has not yet become
clear, but which should be considered a real possibility as
follow up continues into the long term [5, 6]. Unfortunately,
while tolerance of a variety of organ and composite tissue
transplants may be reliably induced in small animal models,
translating these findings to large animal preclinical models
and clinical trials has proved challenging, and to date only
protocols utilizing lymphohematopoietic mixed chimerism
have proved successful at inducing tolerance across genetic
disparities at these levels [7]. The term mixed chimerism
has been subjected to a widely encompassing definition,
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ranging from donor hematopoietic stem cell engraftment
with stable long-termmultilineage contribution, to regimens
using donor bone marrow infusion to achieve transient
mixed chimerism that may or may not be followed by a state
of microchimerism. These various states of chimerism and
the relative role they play in the induction and maintenance
of tolerance of transplanted tissues have been demonstrated
to vary across models and target organs [8].
These results provide proof of concept for clinical trans-
plantation tolerance, and it can be hoped that further devel-
opment of tolerance protocols will overcome the stringent
challenge posed by composite transplants including skin,
and lead to development of clinically applicable protocols
for VCA tolerance. In this paper we will review progress
in the development of mixed-chimerism-based tolerance
protocols, and outline encouraging areas of research with
potential for development of novel alternatives to current
immunosuppressive regimens in vascularized composite
allotransplantation.
2. Mixed Chimerism and Transplant Tolerance
In immunological terms, a chimera is an individual in
whom a proportion of the hematopoietic cell population can
be identified as originating from another individual. This
may occur naturally, as in the case of Owen’s freemartin
cattle [9], but is most usually the result of hematopoietic
cell transplantation [10]. In the context of tolerance induc-
tion, it is also important to differentiate between full and
mixed chimerism. Full chimerism describes the complete
replacement of an individual’s hematopoietic system with
donor cells. This is commonly seen following treatment for
hematological malignancy, but is associated with reduced
immunocompetence and a significant risk of graft versus
host disease (GvHD) [11]. Mixed chimeras, as the name sug-
gests, possess amixture of recipient and donor hematopoietic
cells. Mixed chimerism requires less stringent conditioning
of the recipient, maintains immunocompetence and has
a lower risk of graft versus host disease, and as such is
preferable as a potential tolerance induction strategy [12].
The use of hematopoietic cell transfer in production of
chimeras and hence induction of donor specific tolerance
has been known for many years, and this approach remains
at the forefront of attempts to develop clinically applicable
tolerance induction strategies for all forms of surgical trans-
plantation. Interest in this approach has been maintained
by reports of patients accepting organ transplants without
chronic immunosuppression, having previously received
bone marrow transplants from the same donors [13]. Early
experimental protocols in mice relied on myeloablative
conditioning and complete reconstitution with a donor
hematopoietic stem cell graft in order to achieve engraftment
and chimerism [14]; however such protocols carry signifi-
cant morbidity and a risk of impaired immunocompetence
which would not be considered acceptable outside the field
of hematological malignancy. The development of non-
myeloablative conditioning regimens achieving engraftment
and mixed chimerism with significantly reduced morbidity
represents a key step in the search for clinically relevant
tolerance induction regimens and has been demonstrated
in small animals [15], large animals [16], and in clinical
protocols [17].
It has been proposed that donor stem cell engraftment,
resulting in maintenance of donor cell lineages within the
recipient, provides continued presentation of donor antigen,
facilitating donor-specific tolerance through the same central
and peripheral mechanisms responsible for self-tolerance
(Figure 1) [13]. The presence of antigen presenting cells of
both donor and recipient origin within the thymus will
facilitate clonal deletion of both donor and recipient-reactive
thymocytes, as reviewed by Sykes [12]. It is presumed that
alloreactive thymocytes escaping deletion will be controlled
by T regulatory cells, which may be educated either in the
thymus or in the periphery within transplanted tissues.
Progressive clonal deletion of peripheral T cells has been
identified as an important mechanism [18]. However, non-
deletional mechanisms have also been shown to play a role,
as donor specific tolerance can be demonstrated before clonal
deletion is complete [19–21]. The balance of regulatory and
deletional mechanisms in tolerance is complex, but there is
evidence inmild regimes, achieving low level chimerism, that
regulatory mechanisms predominate [13, 22]. Regulatory
mechanisms appear to retain an important role during
the induction of tolerance by more stringent regimes, but
this gradually declines with time, as progressive deletion of
donor-reactive T cells continues [21, 23].
Interestingly, the requirement for the establishment of
stable mixed chimerism may not be applicable for the long-
term rejection free survival of various organs and tissues.
In both preclinical studies in nonhuman primates, and the
MGH clinical trial, transient mixed chimerism was found
to be sufficient for induction of renal allograft tolerance
[24, 25]. It is hypothesized that T regulatory cells, educated
during the period of chimerism, are responsible for mainte-
nance of tolerance in this scenario. Pronounced FoxP3+ T
cell infiltration in the absence of signs of inflammation or
tissue damage was observed within the kidneys tolerated by
recipients in the nonhuman primate studies, suggesting local
regulation of the immune response within the donor organ
[24]. In contrast to these findings of organ tolerance despite
loss of detectible chimerism, Leventhal and colleagues have
recently reported establishment of durable chimerism and
kidney transplant tolerance, without graft versus host dis-
ease. Non-myeloablative conditioning and transplantation of
an enriched hematopoietic stem cell graft in combination
with an infusion of graft-facilitating cells, composed pri-
marily of plasmacytoid precursor dendritic cells, achieved
chimerism and permitted weaning of immunosuppression in
five of eight patients [26].
In contrast to kidneys, studies in large animal recipients
of bone marrow and vascularized composite allografts
suggest that these transplants may have more stringent
requirements. A series of studies in MGH Miniature Swine
indicate that while tolerance of the musculoskeletal compo-
nents of vascularized composite allografts may be induced
by protocols achieving transient chimerism, tolerance of
skin requires engraftment of donor hematopoietic stem
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1. Donor hematopoietic
stem cells (HSCs) are
isolated from bone marrow
or cytokine-mobilized
peripheral stem cells.
2. Recipients are conditioned with
a non-myeloablative regimen to
control alloreactivity and create
‘space’ for donor HSCs to engraft.
protocols may include total body and
thymic irradiation, T cell depleting
reagents, costimulatory blocking
reagents, and short courses of
conventional immunosuppression.
3. Presence of both donor
and recipient antigen within
the thymus mediates clonal
deletion of both donor-and
recipient-reactive
thymocytes (central
tolerance) and may provide
for the education of Tregs.
4. Stable engraftment of donor HSCs ensures life-long
donor-derived multilineage mixed chimerism (lymphoid
and myeloid), allowing for specific tolerance of donor









Figure 1: Mechanisms of tolerance in mixed chimerism.
cells and persisting mixed chimerism [27–29]. Skin has
long been regarded as the most robust test of transplant
tolerance [30]. Initial studies utilized a heterotopic hind limb
model, with or without skin paddle, transplanted between
MHC-matched, minor antigen mismatched animals, treated
with a 12 day course of Cyclosporine A. All animals in
both groups accepted the musculoskeletal components of
the transplanted limb long-term. Those in the skin-free
transplant group subsequently received frozen donor split
thickness skin grafts, which rejected [31]. Recipients of skin-
bearing transplants demonstrated prolonged skin survival,
in one case to 180 days, but in all cases epidermal rejection
eventually occurred [27]. This state of tolerance to one organ
or tissue, while simultaneously rejecting another, has a long
historical record, as it was first described by Billingham and
Silvers and termed “split tolerance” [32]. These findings are
consistent with previous studies demonstrating that skin
is consistently more prone to rejection than other tissues,
but that primarily vascularized skin appears to enjoy a
survival advantage over conventional skin grafts.While tissue
specific antigens are often offered as a potential explanation
for the difficulty in achieving skin acceptance, a definitive
skin specific antigen is yet to be identified, and other
factors including graft size, the skin immune system and
the inflammatory milieu resulting from a period of relative
ischemia in the absence of primary vascularization have all
been implicated [33–35].
Subsequent studies addressed the important step of
transplantation across major histocompatibility barriers,
once again utilizing the skin-bearing heterotopic limbmodel.
In this series, the musculoskeletal components of the limb
were once again uniformly tolerated, across both single
haplotype and full class I and class II MHC barriers in recip-
ients of hematopoietic stem cell transplantation using either
cytokine-mobilized peripheral blood mononuclear cells or
bone marrow cells. Prolonged skin survival to between 35
and 50 days was observed but tolerance of skin was not
demonstrated [28]. Animals receiving cytokine mobilized
cells received a significantly higher dose of hematopoietic
cells than those receiving bone marrow, and demonstrated
detectable albeit progressively declining peripheral blood
mixed chimerism, while those receiving bone marrow did
not. Regardless, these studies further illustrate that while
kidney tolerance may be achieved by similar protocols in
the context of both transient and long-term chimerism,
induction of tolerance of skin components of VCAs will
requiremore robust inductionmechanisms. The relationship
between chimerism and tolerance has often been contro-
versial [36, 37], and in this model it appears that stable
chimerism is not necessary for tolerance of musculoskeletal
components of the allografts.
In 2009 Horner et al. published a preliminary report
of the successful induction of tolerance to skin across
a major histocompatibility barrier in the MGH minia-
ture swine model in which stable mixed chimerism was
established using a non-myeloablative conditioning regimen
and cytokine mobilized hematopoietic stem cells. Following
confirmation of donor stem cell engraftment, primarily
vascularized skin flaps and conventional skin grafts were
transplanted, and in this experiment one animal demon-
strated tolerance of its flap for over 300 days of follow up.
This tolerance was robust, as demonstrated by the acceptance
of a subsequent donor split thickness skin graft placed
124 days following the original skin flap [29]. Recently,
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similar results in a canine model of vascularized composite
allotransplantation have been reported by Mathes et al.,
with long-term graft survival and stable mixed chimerism
in a MHC-matched, minor antigen mismatched model
[38]. These studies support the hypothesis that engraftment
of donor hematopoietic stem cells, and persisting mixed
chimerism are required for tolerance of skin in these large
animal models.
3. Cellular Therapies in Mixed Chimerism
and VCA Tolerance
Considerable reductions in the toxicity and morbidity of
conditioning regimens have been achieved since the ini-
tial studies utilizing myeloablative protocols, although the
majority of these have been described in small animal mod-
els. Thus, achieving mixed chimerism while minimizing the
adverse effects of conditioning remains a challenging balance
and a variety of novel strategies have been investigated as
potential adjuncts in an effort to enhance engraftment and
mitigate complications such as GvHD.
3.1. T Regulatory Cells. Regulatory cells have been exten-
sively studied in the context of transplantation tolerance.
The existence of a population of lymphocytes capable of
suppressing immune responses was first described 40 years
ago, and shortly thereafter these cells were demonstrated
to facilitate tolerance of non-self antigens in a murine skin
transplant model, demonstrating the potential importance
of these cells in achieving tolerance of the skin component
of VCA [39, 40]. The characterization and diverse functions
of the canonical CD4+CD25+FoxP3+ Treg cell population
has been extensively reviewed [41]. The ability of these cells
to enhance engraftment following allogeneic bone marrow
transplantation was described by Joffre et al. who subse-
quently demonstrated that CD4+CD25+FoxP3+ T regulatory
cells could prevent both acute and chronic rejection of skin
and cardiac allografts [42, 43].
Direct evidence for cellular regulation by CD4+CD25+
T cells has been demonstrated in some murine models
of bone marrow transplantation. Bigenzahn and colleagues
found that depletion of CD25+ cells at the time of bone
marrow transplantation and costimulatory blockade (anti-
CD154 and CTLA4Ig) blocked development of tolerance, but
that late depletion of CD25+ cells failed to abrogate tolerance,
demonstrating that, in this model, the role of Tregs was
most prominent during induction rather than maintenance
phases [44]. Pilat and colleagues recently demonstrated that
recipient T regulatory cells, administered in conjunction
with anti-CD40L mAb and CTLA4Ig costimulatory blockade
and a short course of Rapamycin, could achieve engraftment
and stable multilineage chimerism, and subsequent skin
tolerance, following radiation-free conditioning and conven-
tional dose bone marrow transplantation in a fully mis-
matched murine model [45]. Interestingly, Rapamycin was
found to be an essential component of this protocol, which
is consistent with other studies finding that Rapamycin
facilitates selective expansion of T regulatory cells while
inhibiting clonal proliferation of effector cells [46].
Issa and colleagues in Oxford have reported the devel-
opment of a humanized mouse model, in which they have
extensively investigated the potential of human Tregs as
a tolerance induction strategy for transplantation. They
recently demonstrated the ability of these cells to prevent
transplant arteriosclerosis (a hallmark of chronic graft
rejection), and uniquely, to induce tolerance to human skin
allografts [47]. There is also evidence that, in the context
of bone marrow transplantation, donor CD4+CD25+ cells
may protect against acute graft versus host disease (GvHD)
[48, 49]. Taken together and in combination with the
work done by many other groups, these experiments are
certainly encouraging, but further work is required to refine
the specificity of Treg markers, and to provide evidence
of efficacy in large animal models prior to considering
the therapeutic application of T regulatory cells in clinical
composite tissue allotransplantation.
3.2. Dendritic Cells. The traditional view of dendritic cells
(DCs) as potent inducers of immune reactivity has been
augmented in recent years by the recognition that, as
specialized antigen presenting cells, they have the ability
to facilitate immunologic tolerance [50, 51]. It is logical
that dendritic cells exert their tolerogenic effects through
interaction with T cells, and indeed, they have been shown
to suppress CD4+ and CD8+ T cell proliferation [52], and to
control activation and function of CD4+CD25+Foxp3+ Tregs
[53].
The accepted paradigm states that immature dendritic
cells (characterized by low expression of cell surface MHC
II and costimulatory molecules) induce tolerance upon
interaction with T cells, while mature dendritic cells (high
expressers of MHC II and costimulatory molecules) induce
an effector response from T cells [54]. However, it has
been demonstrated that dendritic cells of both immunogenic
and tolerogenic phenotypes may be directed toward a
change of phenotype by ligation of specific cell surface
receptors [55]. Therefore, while the existence of functionally
distinct subsets of dendritic cells is being continuously
defined and expanded (reviewed in [56]), it seems likely
that the distinction between tolerogenic and immunogenic
roles does not lie along simple divisions between subsets,
and that dendritic cells demonstrate functional plasticity,
although the discriminating factor in this plasticity remains
controversial.
Attempts have been made to exploit the tolerogenic
potential of dendritic cells in animal models of transplanta-
tion with some success. Tolerance of cardiac transplants has
been achieved in rodent models following administration of
donor allopeptide-pulsed DCs in combination with a short
course of antilymphocyte serum [57]. Long term survival
of skin allografts and hind-limb composite tissue allotrans-
plants, has also been demonstrated, in some cases with
demonstrable expansion of Tregs [58–62]. In the context
of mixed chimerism protocols, it has been demonstrated
in a murine model that cotransplantation of bone marrow
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with immature dendritic cells lead to engraftment and stable
multilineage chimerism without cytoreductive conditioning
and with no evidence of graft versus host disease. These
chimeras accepted cardiac allografts long-term, and while
skin tolerance was not achieved, challenge skin grafts did
enjoy significantly prolonged survival [63].
There have been some early studies in nonhuman pri-
mates which have demonstrated the presence of tolerogenic
dendritic cells with the ability to modulate the T cell
response to alloantigens [64], and, it has been demonstrated
that dendritic cells are able to induce tolerance of model
antigens and facilitate expansion of T regulatory cells in
human volunteers [65, 66]. These findings point to the
possibility of “negative cellular vaccines” as a potential route
to tolerance in composite tissue allotransplantation, but
further preclinical work is required [67].
3.3. Mesenchymal Stem Cells. Mesenchymal stem cells
(MSCs) are a component of the bone marrow stroma,
and play homeostatic roles important for hematopoiesis
through synthesis of numerous cytokines and growth factors
including granulocyte colony stimulating factor (G-CSF),
stem cell factor (SCF), Flt-3 ligand and members of the
interleukin family [68, 69]. MSCs have been shown to lack
expression of costimulatory molecules and consequently
to have limited capability for stimulating alloreactive T
cells [70–72]. Furthermore, MSCs have been demonstrated
to possess immunological inhibitory potential, suppressing
proliferation in mixed lymphocyte cultures and prolonging
skin graft survival in a rodent allotransplant model [73, 74].
The natural physiologic role of MSCs within bone mar-
row stroma has been exploited in the successful treatment
of GvHD in patients following bone marrow transplantation
[75], and recently to facilitate engraftment and induction of
tolerance to limb composite tissue allografts in animal mod-
els. Using a rat model, Pan and colleagues performed hind-
limb allotransplantation after having induced chimerism 30
days previously with a regime of antilymphocyte serum,
rapamycin, 3Gy total body irradiation, bone marrow cells
and ex vivo expanded MSCs. Rapamycin was continued
for 100 days, and following cessation of treatment, animals
exhibited stable chimerism, tolerated their transplanted
limb for greater than 100 days without any exogenous
immunosuppression, and showed no evidence of GvHD
[76].
MSCs have also been reported to be a useful adjunct to
bone marrow transplantation for tolerance induction in a
large animal model. In an outbred miniature swine model,
Kuo and colleagues demonstrated survival of heterotopic
hind-limb allotransplants for greater than 200 days in ani-
mals treated with irradiation, bone marrow transplantation,
28 days of cyclosporine, and three doses of donorMSCs (each
of 1 × 107 cells, on days 7, 14, and 21 post limb transplant).
Interestingly, while no signs of GvHD were observed, the
same regime in the absence of MSCs resulted in a maximal
allograft survival of 57 days and symptoms of severe GvHD
ultimately resulting in death [77]. This study provides proof
of principle that MSCs may be an effective adjunct to bone
marrow transplantation in tolerance induction, and taken
together with previously reported clinical use of MSCs for
treatment of GvHD, indicates that this may be a useful and
interesting avenue for further research in composite tissue
allotransplantation.
4. Conclusions and Future Directions
The shared history of reconstructive and transplant surgery
have, over the past 15 years, witnessed a new chapter with
the emergence of vascularized composite allotransplantation
as a viable option for the treatment of patients with severe,
complex extremity and craniofacial defects for which the
outcomes of conventional reconstructive techniques remain
suboptimal. While clinical data demonstrate the short to
medium term efficacy of these procedures, the decision to
prescribe life-long immunosuppression in the treatment of
non-life-threatening condition remains an ethical dilemma.
The induction of donor specific tolerance holds the
potential to avoid both the risks of life-long immuno-
suppression and to prevent chronic rejection. A clinically
applicable tolerance strategy for vascularized composite allo-
transplantation would fundamentally alter the risk-benefit
analysis for potential recipients and could expand availability
of these procedures to patients currently considered high
risk or unsuitable candidates, for example those requiring
restoration of congenital anomalies or following oncological
resection. Skin remains a particularly stringent test of any
transplant tolerance protocol, and while tolerance of skin
has been reported in preclinical studies further work is
required to demonstrate that this can be reliably achieved by
a clinically applicable protocol.
While there is encouraging evidence from small animal
models for a wide variety of tolerance strategies, mixed
chimerism is the only approach to prove successful in large
animal studies, or to reach clinical trials in organ trans-
plantation, and is the established frontrunner in preclinical
studies of composite tissue tolerance. While it has been
shown clinically that transient mixed chimerism and other
immunomodulatory approaches are sufficient for induction
of tolerance of other organs, and can play an important role
in minimization of immunosuppression for VCA [25, 78],
to move toward the goal of true tolerance and immuno-
suppression free VCA acceptance, stable mixed chimerism
appears to have the most promise at this time. Despite a
steady reduction in the toxicity of experimental regimens,
the morbidity associated with the conditioning regimes
required to permit engraftment of hematopoietic stem cells
remains a concern. Despite success in small and now large
animal models translation to clinical application remains
challenging. In addition to the combined kidney and bone
marrow transplantation studies reported by several centers
[25, 26], recent work by Bolan˜os-Meade et al. [79] in the field
of HLA mismatched bone marrow transplantation demon-
strates progress toward establishment of chimerism across
MHC barriers with a low incidence of GvHD suggesting that
the goal of inducing VCA tolerance with mixed chimerism
remains highly possible. In this paper we have reviewed
6 Clinical and Developmental Immunology
a number of adjuvants to the mixed chimerism approach,
which appear to have the potential to enhance engraftment
and to mitigate complications such as GvHD. Some of these
strategies have already been tested in preclinical models
with encouraging results, and it can be hoped that further
translational studies will result in development of safe,
effective tolerance induction protocols for clinical trial in
vascularized composite allotransplantation.
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